NKAP functions as an oncogene in Ewing sarcoma cells partly through the AKT signaling pathway

Li,Feng; Wu,Jing‑Tao; Wang,Peng‑Fei; Qu,Li‑Zhen

doi:10.3892/etm.2019.7925

NKAP functions as an oncogene in Ewing sarcoma cells partly through the AKT signaling pathway

Authors:
- Feng Li
- Jing‑Tao Wu
- Peng‑Fei Wang
- Li‑Zhen Qu
View Affiliations

Affiliations: Department of Joint and Sports Medicine, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277100, P.R. China, Department of Orthopedics Surgery, Tengnan Hospital of Zaozhuang Mining Group, Jining, Shandong 277000, P.R. China, Department of Hand, Foot and Microsurgery, Shandong Energy Zaozhuang Mining Group Central Hospital, Zaozhuang, Shandong 277800, P.R. China, Department of Orthopedics Trauma, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277100, P.R. China
Published online on: August 20, 2019 https://doi.org/10.3892/etm.2019.7925
Pages: 3037-3045
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

NF‑κB activating protein (NKAP) is a highly conserved protein involved in transcriptional repression, immune cell development, maturation, acquisition of functional competency and maintenance of hematopoiesis. In the present study, the function of NKAP in the progress of Ewing sarcoma (ES) was investigated. It was identified that NKAP is highly expressed in ES cells when compared with human mesenchymal stem cells (MSCs). NKAP was knocked‑down in human ES cell lines A673 and RD‑ES using small interfering (si)RNA transfection. The effectiveness of transfection was then verified using reverse transcription‑quantitative PCR and western blot analysis to determine mRNA and protein levels, respectively. The results of the proliferation assays indicated that the knockdown of NKAP inhibited the proliferation and clonogenic abilities of human ES cells. Transwell assays further indicated that cell invasion and migration were significantly inhibited by NKAP knockdown, which may be mediated by downregulation of matrix metalloproteinase (MMP)‑9 activity. Gain‑of‑function analysis also demonstrated the positive role NKAP played in the proliferation, invasion and migration of ES cells. Cell apoptosis was evaluated by flow cytometry, which identified that apoptotic cells were significantly increased when NKAP was silenced. In addition, downregulation of NKAP increased the levels of Bax and cleaved caspase 3, but decreased Bcl2 levels, which suggested that the mitochondrial apoptosis pathway was activated. To explore the action mechanism of NKAP, the status of the AKT signaling pathway in NKAP‑silenced A673 and RD‑ES cells was investigated. Results indicated that NKAP knockdown led to decreased phosphorylation of AKT and expression of cyclin D1, a down‑stream effector of the AKT signaling pathway, suggesting inactivation of the AKT signaling pathway. In conclusion, the present study revealed that NKAP promoted the proliferation, migration and invasion of ES cells, at least partly, through the AKT signaling pathway, providing new approaches for the therapeutic application of NKAP in ES.

View Figures

View References

1	Esiashvili N, Goodman M and Marcus RB Jr: Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades-surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 30:425–430. 2008. View Article : Google Scholar : PubMed/NCBI
2	Galyfos G, Karantzikos GA, Kavouras N, Sianou A, Palogos K and Filis K: Extraosseous ewing sarcoma: Diagnosis, prognosis and optimal management. Indian J Surg. 78:49–53. 2016. View Article : Google Scholar : PubMed/NCBI
3	Max D, Kuehnoel CD, Burdach S, Niu L, Staege MS and Foell JL: Indoleamine-2,3-dioxygenase in an immunotherapy model for ewing sarcoma. Anticancer Res. 34:6431–6441. 2014.PubMed/NCBI
4	Ladenstein R, Poetschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, et al: Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial. J Clin Oncol. 28:3284–3291. 2010. View Article : Google Scholar : PubMed/NCBI
5	Sand LG, Szuhai K and Hogendoorn PC: Sequencing Overview of ewing sarcoma: A journey across genomic, epigenomic and transcriptomic landscapes. Int J Mol Sci. 16:16176–16215. 2015. View Article : Google Scholar : PubMed/NCBI
6	Chen D, Li Z, Yang Q, Zhang J, Zhai Z and Shu HB: Identification of a nuclear protein that promotes NF-kappaB activation. Biochem Biophys Res Commun. 310:720–724. 2003. View Article : Google Scholar : PubMed/NCBI
7	Burgute BD, Peche VS, Steckelberg AL, Glöckner G, Gaßen B, Gehring NH and Noegel AA: NKAP is a novel RS-related protein that interacts with RNA and RNA binding proteins. Nucleic Acids Res. 42:3177–3193. 2014. View Article : Google Scholar : PubMed/NCBI
8	Thapa P, Chen MW, McWilliams DC, Belmonte P, Constans M, Sant'Angelo DB and Shapiro VS: NKAP Regulates Invariant NKT Cell Proliferation and Differentiation into ROR-gammat-Expressing NKT17 Cells. J Immunol. 196:4987–4998. 2016. View Article : Google Scholar : PubMed/NCBI
9	Pajerowski AG, Nguyen C, Aghajanian H, Shapiro MJ and Shapiro VS: NKAP is a transcriptional repressor of notch signaling and is required for T cell development. Immunity. 30:696–707. 2009. View Article : Google Scholar : PubMed/NCBI
10	Thapa P, Das J, McWilliams D, Shapiro M, Sundsbak R, Nelson-Holte M, Tangen S, Anderson J, Desiderio S, Hiebert S, et al: The transcriptional repressor NKAP is required for the development of iNKT cells. Nat Commun. 4:15822013. View Article : Google Scholar : PubMed/NCBI
11	Hsu FC, Pajerowski AG, Nelson-Holte M, Sundsbak R and Shapiro VS: NKAP is required for T cell maturation and acquisition of functional competency. J Exp Med. 208:1291–1304. 2011. View Article : Google Scholar : PubMed/NCBI
12	Dash B, Shapiro MJ, Chung JY, Romero Arocha S and Shapiro VS: Treg-specific deletion of NKAP results in severe, systemic autoimmunity due to peripheral loss of Tregs. J Autoimmun. 89:139–148. 2018. View Article : Google Scholar : PubMed/NCBI
13	Worlitzer MM and Schwamborn JC: The Notch co-repressor protein NKAP is highly expressed in adult mouse subventricular zone neural progenitor cells. Neuroscience. 266:138–149. 2014. View Article : Google Scholar : PubMed/NCBI
14	Pajerowski AG, Shapiro MJ, Gwin K, Sundsbak R, Nelson-Holte M, Medina K and Shapiro VS: Adult hematopoietic stem cells require NKAP for maintenance and survival. Blood. 116:2684–2693. 2010. View Article : Google Scholar : PubMed/NCBI
15	Li T, Chen L, Cheng J, Dai J, Huang Y, Zhang J, Liu Z, Li A, Li N, Wang H, et al: SUMOylated NKAP is essential for chromosome alignment by anchoring CENP-E to kinetochores. Nat Commun. 7:129692016. View Article : Google Scholar : PubMed/NCBI
16	Liu J, Wang H, Yin Y, Li Q and Zhang M: NKAP functions as an oncogene and its expression is induced by CoCl2 treatment in breast cancer via AKT/mTOR signaling pathway. Cancer Manag Res. 10:5091–5100. 2018. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
19	Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C: PI3K/Akt and apoptosis: Size matters. Oncogene. 22:8983–8998. 2003. View Article : Google Scholar : PubMed/NCBI
20	Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B and Ribas A: Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer. 13:832014. View Article : Google Scholar : PubMed/NCBI
21	Choi BD, Jeong SJ, Wang G, Park JJ, Lim DS, Kim BH, Cho YI, Kim CS and Jeong MJ: Secretory leukocyte protease inhibitor is associated with MMP-2 and MMP-9 to promote migration and invasion in SNU638 gastric cancer cells. Int J Mol Med. 28:527–534. 2011.PubMed/NCBI
22	Zhang X, Min J, Wang Y, Li Y and Li H, Liu Q, Liang X, Mu P and Li H: RABEX-5 plays an oncogenic role in breast cancer by activating MMP-9 pathway. J Exp Clin Cancer Res. 32:522013. View Article : Google Scholar : PubMed/NCBI
23	Gui D, Guo Y, Wang F, Liu W, Chen J, Chen Y, Huang J and Wang N: Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo. PLoS One. 7:e398242012. View Article : Google Scholar : PubMed/NCBI
24	Martinou JC and Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell. 21:922011. View Article : Google Scholar : PubMed/NCBI
25	Yang TQ, Lu XJ, Wu TF, Ding DD, Zhao ZH, Chen GL, Xie XS, Li B, Wei YX, Guo LC, et al: MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-kappaB1/MMP-9 signaling pathway. Cancer Sci. 105:265–271. 2014. View Article : Google Scholar : PubMed/NCBI
26	Radha G and Raghavan SC: BCL2: A promising cancer therapeutic target. Biochim Biophys Acta Rev Cancer. 1868:309–314. 2017. View Article : Google Scholar : PubMed/NCBI
27	Martini M, De Santis MC, Braccini L, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
28	Polivka J Jr and Janku F: Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 142:164–175. 2014. View Article : Google Scholar : PubMed/NCBI